In previous studies on SGLT-2 inhibitors, relevant literature noted that under the guidance of doctors, the probability of urinary tract infections can be reduced by strengthening personal hygiene practices,[21] which may explain why we did not observe more urinary tract infections with oral SOTA use in patients with T1DM. The gene discussed is SLC5A2; the disease is type 1 diabetes mellitus.